Pharma Titans Collide: Sanofi Makes Massive $9.5 Billion Play for Blueprint Medicines to Dominate Rare Immunology Sanofi acquires Blueprint Medicines for $9.5B, boosting its rare immunology portfolio and accelerating game-changing…
Dave Williamson leads innovations at Abzena, focusing on bioconjugates and ADCs to transform patient care globally. His diverse experiences, from the U.S. Army to pharmaceutical technology, fuel his passion for…
A strategic partnership between Wacker Biotech and RNAV8 Bio aims to revolutionize mRNA-based therapies. The collaboration focuses on optimizing untranslated regions (UTRs) in mRNA strands to enhance drug effectiveness. Improved…